Danaher Corporation
DHR Healthcare Diagnostics & Research
Danaher Corporation’s revenue for fiscal 2025 (year ended December 2025) was $24.6 billion, up 2.90% from fiscal 2024. In the quarter to June 2026, revenue grew 5.54%, EPS grew 59.7%, free cash flow grew 15.6% and total debt rose 49.2%, each against the same quarter a year earlier. Member of the S&P 500.
Follow DHR
Danaher Corporation (DHR) Return on equity
Danaher Corporation's return on equity over the twelve months to 30 June 2026 was 7.63%, up 0.6 percentage points from fiscal 2025 (7.08%). Over the past ten years it has ranged from 7.08% (fiscal 2025) to 16.0% (fiscal 2021) — the current reading is the lowest in ten years. That is above the Diagnostics & Research industry median of −2.92% and above the Healthcare sector median of −31.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 7.08% | (0.49) |
| FY2024 | 7.57% | (1.74) |
| FY2023 | 9.31% | (6.42) |
| FY2022 | 15.7% | (0.26) |
| FY2021 | 16.0% | 5.22 |
| FY2020 | 10.8% | 0.44 |
| FY2019 | 10.3% | 0.62 |
| FY2018 | 9.71% | (0.37) |
| FY2017 | 10.1% | (0.82) |
| FY2016 | 10.9% | (3.32) |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| IDXX IDEXX Laboratories, Inc. compare | 74.2% |
| ILMN Illumina, Inc. compare | 32.4% |
| IQV IQVIA Holdings Inc. compare | 22.8% |
| A Agilent Technologies, Inc. compare | 21.0% |
| TMO Thermo Fisher Scientific Inc. compare | 13.5% |
| DHR Danaher Corporation | 7.63% |
| WAT Waters Corporation compare | 1.92% |
| NTRA Natera, Inc. compare | −12.5% |
| MTD Mettler-Toledo International, Inc. compare | −736.4% |
| Diagnostics & Research industry median | −2.92% |
| Healthcare sector median | −31.3% |
| Market median | 1.35% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on DHR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement